Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
This study has been completed.
Study NCT00154388   Information provided by Novartis
First Received: September 9, 2005   Last Updated: November 20, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Life Threatening Diseases
Additional conditions recognized in this trial
Rare Diseases
More general conditions related to this trial
Disease Attributes
Pathologic Processes
Interventions listed in this trial
Imatinib mesylate
Additional drug interventions recognized in this trial
Imatinib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services